Natera (NTRA) Stock

Natera, a top company in cfDNA testing, has experienced significant growth and is close to making a profit, but its current market value seems too high. The company faces strong competition from others like Guardant Health and Quest Diagnostics, along with legal challenges that could be risky. While Natera's revenue is mainly boosted by its oncology division, especially the Signatera test, future growth might slow down as it approaches its total addressable market.

Natera (NTRA) has reached a key support level, making it a potentially strong stock choice based on technical analysis. The stock has also broken through the resistance at the 20-day moving average, indicating a positive trend in the short term.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that its Prospera Lung test has fulfilled the coverage criteria set by the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage is relevant for SLT patients undergoing monitoring. SLT patients account for about 20% of all lung transplants in the U.S.1, and their numbers are rising.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that it will showcase new data on SignateraTM at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13 in San Antonio, TX. Natera and its partners will present six abstracts in total. "We are excited to share this new information on Signatera at SABCS, highlighting our dedication to providing evidence of its clinical benefits for patients."

Guardant Health has achieved one of the largest verdicts for false advertising in history, marking an important win for colorectal cancer patients who may benefit from their product, Guardant Reveal™. A jury in California's U.S. District Court ruled unanimously in favor of Guardant Health in their lawsuit against Natera, which was accused of misleading oncologists to hinder competition. This decision highlights the significance of accurate information in the healthcare industry.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing, has reached an important achievement by publishing over 100 peer-reviewed articles on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Several validation studies for Signatera have appeared in prestigious journals such as Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology.

The main figures for Natera (NTRA) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.

Natera (NTRA) reported a quarterly loss of $0.26 per share, which is better than the Zacks Consensus Estimate of a $0.57 loss. This is an improvement compared to a loss of $0.95 per share from the same period last year.

Natera (NTRA) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.